financetom
Business
financetom
/
Business
/
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care
Sep 15, 2025 4:11 AM

ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/ -- Avanos Medical, Inc. ( AVNS ) , a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.

Nexus is the maker of the proprietary TKO® anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).

The acquisition adds complementary technology to Avanos' Specialty Nutrition Systems business and reinforces the company's focus on safe, reliable therapy delivery for the neonatal patient population.

"This acquisition is a clear extension of our strategy to deliver smarter, safer solutions across the critical care spectrum," said Dave Pacitti, Avanos chief executive officer. "We are proud to add the Nexus TKO® technology and the full breadth of Nexus' offerings to our portfolio as we continue investing in meaningful innovation that helps clinicians provide consistent care and improve outcomes for patients who need it most."

The TKO® needleless connector features a patented, pressure-activated tri-seal silicone valve that minimizes blood reflux – a known contributor to catheter occlusions, therapy delays, and infection risk during IV-based nutrition and medication delivery.*

"Nexus TKO® fits naturally into our Specialty Nutrition Systems business and is expected to deliver immediate value in NICU and PICU care," said Kerr Holbrook, Avanos' chief commercial officer. "It's a practical, trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease."

Avanos financed the acquisition with available cash. The company expects the acquisition to be immediately accretive to both revenue growth and earnings per share.

About Avanos Medical ( AVNS )

Avanos Medical ( AVNS ) is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical ( AVNS ) on X (@AvanosMedical), LinkedIn and Facebook.

About Nexus Medical

Founded in 2001, Nexus Medical invented the anti-reflux category in needleless connectors to solve the unintended consequences of blood reflux in IV catheters, including intraluminal thrombotic occlusions, catheter failure, and infections. As the most studied needleless connector on the market, the Nexus TKO® anti-reflux technology is an evidence-based way to simplify the complexity of IV therapy and improve patient safety. For more information, call (913) 451-2234 or visit www.nexusmedical.com.

*CLAIM ON FILE

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/avanos-medical-acquires-nexus-medical-to-strengthen-nutrition-and-medication-delivery-in-critical-care-302555789.html

SOURCE Avanos Medical ( AVNS )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Satellos Bioscience Raises $57 Million in Public Offering
Satellos Bioscience Raises $57 Million in Public Offering
Dec 20, 2024
09:47 AM EST, 12/20/2024 (MT Newswires) -- Satellos Bioscience ( MSCLF ) on Friday said it issued 63.3 million equity securities for proceeds of about $57 million. We are thrilled to raise USD$40 million in capital from high-quality healthcare specialized investors to further fund the advancement of our Phase 2 clinical program for SAT-3247, said Satellos Chief Executive Frank Gleeson....
Why Is Penny Stock Foresight Autonomous Stock Gaining Today?
Why Is Penny Stock Foresight Autonomous Stock Gaining Today?
Dec 20, 2024
Foresight Autonomous Holdings Ltd. ( FRSX ) shares saw a boost on Friday following the announcement of a multi-phase collaboration between its subsidiary, Eye-Net Mobile Ltd., SoftBank Corp., and a Japanese vehicle manufacturer. The agreement focuses on evaluating Eye-Net’s cellular vehicle-to-everything (C-V2X) technology, which could play a critical role in advanced driver assistance systems (ADAS) and set new standards for...
Soccer-Netflix inks broadcast deal with FIFA for 2027 and 2031 women's World Cups
Soccer-Netflix inks broadcast deal with FIFA for 2027 and 2031 women's World Cups
Dec 20, 2024
Dec 20 (Reuters) - FIFA and Netflix ( NFLX ) have signed a deal to broadcast the 2027 and 2031 editions of the women's World Cup in the United States, world soccer's governing body said on Friday. As a marquee brand and FIFA's new long-term partner, Netflix ( NFLX ) has shown a very strong level of commitment to growing...
Activist investor Browning West builds over 4% stake in flight simulator firm CAE
Activist investor Browning West builds over 4% stake in flight simulator firm CAE
Dec 20, 2024
Dec 20 (Reuters) - Activist investor Browning West said on Friday it has built a 4.3% stake in CAE, pushing to have a say in hiring the flight simulator maker's new top boss. CAE had said in November its current CEO Marc Parent would leave the Canadian firm after 15 years. We urge the Board not to act hastily in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved